Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM471-1 capsules in anti-NMDAR or anti-LGI1 autoimmune encephalitis (Phase II, randomized, double-blind, placebo-controlled)
CTR20263267Phase 2Active
- Sponsor
- Zhiwei Pharma
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TM471-1 in Autoimmune Encephalitis (AE), Anti-leucine-rich glioma inactivated 1 encephalitis, sponsored by Zhiwei Pharma. Started Aug 2026; status: active.
02
Drugs
TM471-1
03
Conditions
Autoimmune Encephalitis (AE)Anti-leucine-rich glioma inactivated 1 encephalitis
Beyond the preview
Go deeper on CTR20263267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263267.